Clinical TrialsAlpha Tau Medical announced that the first patient has been treated in the U.S. pilot study of Alpha DaRT in patients with pancreatic cancer.
Financial PositionAt the end of June 2025, the company had $83.3M in cash.
Regulatory ApprovalAlpha Tau Medical announced that it has secured a radioactive material license from the New Hampshire Bureau of Public Health Protection, Radiological Health Section, following completion of the first phase of construction of its commercial scale manufacturing facility in Hudson, NH.